
==== Front
Acta Biochim Biophys Sin (Shanghai)
Acta Biochim Biophys Sin (Shanghai)
ABBS
Acta Biochimica et Biophysica Sinica
1672-9145
1745-7270
Science Press

39126246
10.3724/abbs.2024137
Research Article
Immunoglobulin G glycosylation and its alterations in aging-related diseases
IgG glycosylation with aging-related diseases
Wu Yongqi
Zhang Zhida
Chen Lin
Sun Shisheng *
Laboratory for Disease Glycoproteomics College of Life Sciences Northwest University Xi’an 710069 China
† These authors contributed equally to this work.

Correspondence address. Tel: +86-29-88302411; suns@nwu.edu.cn
8 8 2024
25 8 2024
56 8 12211233
14 5 2024
18 7 2024
© The Author(s) 2021.
2024
The Author(s)
0
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Immunoglobulin G (IgG) is an important serum glycoprotein and a major component of antibodies. Glycans on IgG affect the binding of IgG to the Fc receptor or complement C1q, which in turn affects the biological activity and biological function of IgG. Altered glycosylation patterns on IgG emerge as important biomarkers in the aging process and age-related diseases. Key aging-related alterations observed in IgG glycosylation include reductions in galactosylation and sialylation, alongside increases in agalactosylation, and bisecting GlcNAc. Understanding the role of IgG glycosylation in aging-related diseases offers insights into disease mechanisms and provides opportunities for the development of diagnostic and therapeutic strategies. This review summarizes five aspects of IgG: an overview of IgG, IgG glycosylation, IgG glycosylation with inflammation mediation, IgG glycan changes with normal aging, as well as the relevance of IgG glycan changes to aging-related diseases. This review provides a reference for further investigation of the regulatory mechanisms of IgG glycosylation in aging-related diseases, as well as for evaluating the potential of IgG glycosylation changes as markers of aging and aging-related diseases.

IgG
glycosylation
inflammation
aging
aging-related diseases
the grants from the National Natural Science Foundation of ChinaNo. 22374117 the National Key Research and Development Program of ChinaNo. 2019YFA09005200 the Natural Science Foundation of Shaanxi ProvinceNos. 2024-JC-TBZC-06 2023-JC-ZD-46 2023-JC-QN-0234 and Shaanxi Fundamental Science Research Project for Chemistry and BiologyNo. 23JHZ006 This work was supported in part by the grants from the National Natural Science Foundation of China (No. 22374117), the National Key Research and Development Program of China (No. 2019YFA09005200), the Natural Science Foundation of Shaanxi Province (Nos. 2024-JC-TBZC-06, 2023-JC-ZD-46 and 2023-JC-QN-0234), and Shaanxi Fundamental Science Research Project for Chemistry and Biology (No. 23JHZ006).CitationY Wu, Z Zhang, L Chen, S Sun. Immunoglobulin G glycosylation and its alterations in aging-related diseases. Acta Biochim Biophys Sin, 2024, Vol.: fpage–lpage, https://doi.org/10.3724/abbs.2024137
Crossmark2024/8/5 13:55:45
AuthorMarkY Wu
AuthorMarkCiteY Wu, Z Zhang, L Chen, S Sun.
article-titleImmunoglobulin G glycosylation and its alterations in aging-related diseases
==== Body
pmcIntroduction

Aging is a multifaceted biological process involving a gradual overall decline in physiological function and homeostasis over time, making individuals increasingly susceptible to a spectrum of chronic and degenerative conditions [1]. This progressive decline encompasses various cellular, molecular, and systemic changes, including genomic instability, telomere shortening, epigenetic alterations, mitochondrial dysfunction, and proteostasis and inflammatory pathway dysregulation [2]. Aging is jointly regulated by a variety of genetic and epigenetic factors, including the abnormal expressions of aging-related genes, increased DNA methylation levels, altered histone modifications, and disrupted protein translation homeostasis [3]. This regulation exhibits significant variability, heterogeneity, and plasticity, reflecting the complex interplay between genetic predispositions and epigenetic influences [3]. Age-related diseases, such as Alzheimer’s disease, cardiovascular disease, metabolic disorders, and chronic inflammation, represent significant burdens on global health and pose formidable challenges to healthcare systems worldwide [4]. These diseases often share common risk factors and pathological mechanisms with aging, suggesting intricate connections between the aging process and disease pathogenesis [ 5, 6].

Protein glycosylation refers to the enzymatic process of attaching carbohydrate molecules via covalent bonds to specific functional groups on proteins [7]. The “paracentral dogma” hypothesis, which proposes glycosylation as a third fundamental life code after DNA/RNA and proteins [8], underscores the crucial role of sugar codes in co- and post-translational modifications (PTMs). Glycosylation enhances the classical central dogma by providing an additional layer of regulation and information that is crucial for protein folding, stability, cell‒cell communication, and signaling. Protein glycosylation, which is influenced by both genetic and epigenetic factors, plays a pivotal role in numerous cellular signaling and communication events [9]. Glycomedicine refers to glycomics- and glycoproteomics-based biomarkers and therapeutic target discovery; therefore, it has great potential to provide a new dimension of medical science toward better disease diagnosis and drug discovery [10].

Dysregulation of N-glycosylation has been implicated in the aging process and age-related diseases [ 11‒ 13]. In particular, increasing evidence has shown that significant glycan structure alterations in immunoglobulins (Igs) are closely associated with human aging and various aging-related diseases [13]. Immunoglobulin G (IgG) N-glycosylation is thought to be the link between the genetic code and the cellular environment. The environment can strongly influence the inflammatory properties (pro- or anti-inflammatory) of IgGs by regulating their glycosylation. Given the high abundance and important immune functions of IgG in the human body, elucidating the changes in IgG glycosylation associated with aging and aging-related diseases is crucial for obtaining a better understanding of human aging and its associated diseases.

Several excellent reviews have summarized the role of IgG glycosylation in the immune system [14], inflammation [15], cancer [16], and infectious diseases [17]. A review also discussed the potential roles of IgG glycosylation as a marker for biological aging [18]. In this review, we further summarize recent research advances on IgG glycosylation alterations associated with aging and aging-related diseases ( Figure 1), the effects of glycosylation on IgG functions, and the pathogenesis of age-related diseases. In addition, the potential of IgG glycosylation changes as biomarkers for the diagnosis and treatment of aging and age-related diseases is discussed. This review will help readers understand the relationship between IgG glycosylation changes and aging-related diseases and provide important insights and directions for future research in the field of aging glycobiology. Figure 1

Overview of IgG glycosylation alterations associated with aging and aging-related diseases

Overview of IgG

Immunoglobulins play an important role in the adaptive immune response. They consist of two identical light and heavy chains linked by disulfide bonds to form a nearly “Y”-shaped structure. Each heavy chain contains 3‒4 constant regions (CH) and one variable region (VH), while each light chain contains one constant region (CL) and one variable region (VL). Each variable region contains three highly variable ring-structured complementary decision regions (CDRs), and six CDRs in each arm of the antibody’s Y-shaped structure work in concert to form an antigen-binding site, so the Y-shaped arm region of the antibody is known as the antigen-binding region (Fab), which operates like a signal receiver. The fragment crystallizable region (Fc), which consists of two or three constant structural domains per heavy chain [19], transmits signals downstream to various effector cells of the immune system. The Fab region recognizes and binds to specific antigens, while the Fc region interacts with different Fcγ receptors expressed on the surface of immune effector cells to activate downstream pathways [ 20, 21].

There are five isotypes of immunoglobulins (IgM, IgD, IgG, IgA, and IgE) in humans, which are distinguished by the C-terminal region of the heavy chain [22] ( Figure 2A). IgG, which is normally secreted by B cells and plasma cells and is present as a monomer, is the predominant immunoglobulin (~75%) and the most abundant glycoprotein (~10 mg/mL) in human serum [ 23, 24]. There are four subclasses or isotypes of IgG antibodies in human (IgG1–4) and mouse (IgG1, IgG2a, IgG2b, and IgG3) [25]. IgG distribution abundance in human serum is as follows: IgG1 (60%), IgG2 (25%), IgG3 (10%), and IgG4 (5%). The number of disulfide bonds in the hinge region varies among IgG isoforms, with IgG1 and IgG4 containing two interchain disulfide bonds in the hinge region, IgG2 having four disulfide bonds, and IgG3 having 11 disulfide bonds [26] ( Figure 2B). Crystallographic data for the whole IgG molecule are still limited because the flexible nature of the hinge region prevents crystallization, unlike the cumulative crystal structure of Fab and Fc fragments in the complex. To date, only four crystal structures have provided entire views of the IgG structure: PDB codes 1igt, 1igy, 1hzh, and 5dk3 for mouse IgG1, mouse IgG2a, human IgG1, and humanized IgG4 structures, respectively [ 27‒ 30]. The biological functions of these subtypes are also different. IgG1 is produced primarily through the induction of responses to soluble protein antigens and membrane proteins, and a lack of IgG1 leads to a decrease in overall IgG levels [ 31, 32]. IgG2 is the only antibody that can respond to bacterial capsule polysaccharide antigens. Increased susceptibility to certain bacterial infections is associated with IgG2 deficiency, which suggests that IgG2 plays a role in defending against these pathogens [33]. IgG3 antibodies are particularly effective in the induction of effector functions. As a potent pro-inflammatory antibody, its shorter half-life may function to limit the potential for excessive inflammatory responses [34]. IgG4 antibodies are usually formed after repeated or long-term exposure to antigens in non-infected environments and may become major subclasses [35]. The structure, function, antigen binding, immune complex formation, complement activation, effector cell triggering and half-life of the different IgG subtypes have been described in detail in previous reviews and will not be repeated and discussed further here [25]. Figure 2

IgG basic structure and subclasses

(A) Schematic representation of IgG. (B) Four subclasses of IgG, namely, IgG1, IgG2, IgG3, and IgG4.

IgG Glycosylation

Glycosylation, one of the most common post-translational modi-fications in mammalian cells, impacts many biological processes, such as cell adhesion, proliferation and differentiation. There are two main types of glycosylation of proteins in mammals: N-glycosylation and O-glycosylation [36]. Notably, the structure and effector functions of IgG are regulated by N-glycosylation, including galactosylation, sialylation, core-fucosylation, as well as bisecting GlcNAcylation, which will be further described in details [ 21, 37]. N-glycosylation involves the attachment of glycans to the asparagine (Asn) side chain nitrogen atom, specified by the consensus sequence Asn–X–Ser/Thr (X=amino acid except proline) [23]. N-Linked glycans can be found at the Fab and Fc fragments of all IgG subclasses [ 38, 39]. IgG has a conserved N-glycosylation site at Asn297 in the CH2 domain of the Fc region. Our team previously conducted a comprehensive characterization of the N-glycosylations of the four IgG isoforms using self-developed StrucGP software, in which 25 N-glycan structures were identified in IgG1, whereas fewer N-glycan structures were identified in IgG2-4 than in IgG1 [40]. Most of the identified site-specific glycans (84.6%) were core fucosylated, which is consistent with previous studies [ 41, 42] ( Figure 3). Depending on their presence and composition, antigen binding and effector functions such as phagocytosis, complement activation and inflammatory processes are induced with varying effectiveness [ 20, 43]. In addition, N- and O-linked glycans were found in the Fc fusion protein atacicept [44]. O-glycosylation of the amino acid serine (Ser) or threonine (Thr) is rare in IgG. O-glycosylation has been reported for various immunoglobulins. O-glycans are found in the hinges of human IgA1, IgD and mouse IgG2b [ 45‒ 47]. O-glycosylation in the hinge of murine IgG2b was found to protect against proteolytic digestion. A recent study reported that partial O-glycans were detected on threonine residues in the hinge zone of IgG3 [48]. There is a paucity of information regarding IgG O-glycosylation. In this paper, we will primarily focus on the N-glycosylation of immunoglobulin G. Figure 3

N-Glycan structures of human IgG [40]

Biosynthesis of N-glycans on IgG

Protein glycosylation is a complex, multistep process that involves the use of approximately 200 glycosyltransferases that determine which proteins are glycoproteins. IgG N-glycan attachment and maturation occur in the endoplasmic reticulum and Golgi apparatus with the help of glycotransferases and glycosidases [49]. N-linked glycosylation in most eukaryotes follows a similar initial processing pathway within the endoplasmic reticulum. In this paper, we will provide a brief description of the biosynthesis pathway of N-glycans on IgG. This pathway begins with the generation of a lipid linked oligosaccharide (LLO) by multiple asparagine-linked N-glycosylation processing enzymes (ALGs). Lipoglycan precursors (Glc3Man9GlcNAc2 oligosaccharides) are transferred to the glycosylation site Asn297 of the IgG heavy chain by multisubunit oligosaccharyltransferase (OST) of the endoplasmic reticulum. After moving to the cis-Golgi apparatus, three mannose residues are trimmed by α-Man I, and one GlcNAc from UDP-GlcNAc is added to the terminal mannose residue at the α1-3 branch of the oligosaccharide by GnT-II. In addition, FUT8 transfers the fucose moiety from GDP-β-L-fucose to the innermost GlcNAc residue in the N-glycan, and a “bisecting” GlcNAc can be added to the innermost Man residue by one of many GlcNAc transferases (GNTIII) that play a role in generating branches. These antennae are further extended by the addition of galactose (Gal) residues via β-1,4 linkages. These branches can be further modified in several ways, including GlcNAc-Gal extensions (LacNAc) or the addition of a second Gal residue in some mammals via an α-1,3 linkage, which can elicit an immune response in humans. The β-1,4-linked Gal residues are then often capped with sialic acid via α-2,3 or α-2,6 linkages [ 7, 50] ( Figure 4). Figure 4

Brief schematic diagram of the IgG N-glycan synthesis pathway

Galactosylation

Galactosylation occurs in the Golgi apparatus and is mediated by galactosyltransferase, which works by catalyzing the linkage of galactose in uridine diphosphate galactose (UDP-Gal) to N-acetylglucosamine. The enzyme β1,4-galactosyltransferase, also called β-N-acetylglucosaminyl-glycopeptide β1,4-galactosyltransferase, is a trans-Golgi-resident enzyme [51]. The level of galactosylation of IgG changes slowly and progressively with aging. The abundance of agalactosylated IgG N-glycans increased from 20% at 25 years of age to 40% by 70 years of age, peaking in >90-year-old subjects [ 52‒ 55]. IgG galactosylation appears to be, at least in part, driven by estrogen concentrations. This is evidenced by increased levels during pregnancy and decreased levels after menopause. In addition, an endocrine manipulation study confirmed that estrogen is an in vivo regulator of IgG galactosylation in both females and males, suggesting a gender-dependent mechanism of immune response regulation [ 54, 56, 57].

Sialylation

Sialylation involves the addition of terminal sialic acid to cell membrane glycoproteins and is mediated by sialyltransferases (ST3GAL/ST6GAL α2,3/α2,6-sialyltransferase), which are involved in embryonic development, neurodevelopment, reprogramming, tumorigenesis and immune response processes. Sialylated Fc N-glycans are mediators of anti-inflammatory processes; however, the underlying mechanisms are still under discussion [58]. Studies have shown significantly higher levels of sialylation (especially disialylation) in Fabs than in fragment crystallizable (Fc) glycans. Studies in pediatric populations analyzing mainly Fc glycans have revealed a decrease in the abundance of sialic acid glycans up to 10 years of age, after which the trend may reverse, accompanied by dynamic changes in the abundance of galactosylated glycans. One study found no age-related differences in total IgG sialylation levels, suggesting that age-related changes are driven by changes in Fc chain glycan abundance [ 39, 59].

Core fucosylation

Core fucosylation, which is catalyzed by alpha-(1,6)-fucosyltransferase 8 (FUT8), is particularly common in mammals. FUT8 transfers fucose from GDP-β-L fucose to the GlcNAc residue in the innermost layer of the N-glycan [60]. In contrast to most other plasma proteins that are not core fucose-modified, more than 90% of serum IgGs contain the core fucose modification of the first N-acetylglucosamine (GlcNAc) in the core structure of the IgG glycan [ 61, 62]. A slight decrease in core fucosylation on IgGs has been reported in adolescents compared with children [ 59, 63], implying that alterations in core fucosylation might be associated with aging.

Bisection

Bisection refers to the attachment of a GlcNAc residue to the core beta-mannose residue of an N-glycan with β1,4-linkage and is catalyzed by β1,4-N-acetylglucosaminyltransferase III (also known as GnT-III, GlcNAcT-III or MGAT3). Bisected GlcNAc plays a regulatory role in the biosynthesis of complex and hybrid types of oligosaccharides [ 64‒ 66]. Even though the bisecting glycans account for only a small proportion of IgG glycans (approximately 10%–15%) [39] and no significant changes have been observed in most age-related studies, a slightly elevated level of bisecting linkages in adult males but not in females was reported in a study published in 2011 [67].

Changes in IgG Glycosylation Mediate Body Inflammation

The ability of IgG antibodies to mediate effector functions arises from their capacity to bridge antigen binding through the Fab domain with the recruitment of effector cells through interactions between the Fc domain and the Fcγ receptor (FcγR) family. Within the CH2 domain, IgG possesses recognition regions for the initial complement protein C1q as well as the FcγR family. FcγRs are composed of type I (FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, and FcγRIIIb) and type II receptors (DC-SIGN and CD23) [68]. The composition of glycans in the Fc domain impacts receptor binding. Due to glycan modifications, these two types of receptors can be distinguished by their ability to interact with Fc domains, i.e., binding to activating FcγRs promotes an inflammatory response, whereas binding to inhibitory FcγRs activates an anti-inflammatory response. Differences in the N-glycosylation of IgG subclasses and CH2 structural domains may lead to structural variation in IgG Fc structural domains, which leads to human immune diversity through FcγR-mediated cellular functions.

It is well known that the addition of each monosaccharide residue to the glycan chain can significantly alter the effect of IgG. A decrease in galactosylation has been observed in many inflammatory diseases, while an increase in galactosylation is usually associated with a decrease in inflammatory activity. This may be due to high galactosylation of IgG by C1q binding to enhance complement activity [ 69, 70]. IgG sialylation has been associated with reduced inflammation and pathological conditions. Specifically, anti-inflammatory activity is driven by antibodies modified with α2,6-sialylation. Fc sialylation reduces binding to Type I FccRs while enabling the engagement of Type II FccRs. In the presence of sialylated Fc glycans, increased Type II FcγR signaling further triggers anti-inflammatory activity [ 14, 71] ( Figure 5). A classic example of this is the administration of high-dose intravenous immunoglobulin (IVIg) during acute inflammatory diseases such as immune thrombocytopenia, Kawasaki disease, chronic inflammatory demyelinating polyneuropathy and Guillain–Barré syndrome. IVIg is pooled IgG from thousands of donors, and its anti-inflammatory activity is mediated by the minor subset of IgGs within the pool that contain sialylated Fcs. Therefore, anti-inflammatory activity can be enhanced by increasing the abundance of sialylated Fc in IgG pools [ 72, 73]. Afucosylated IgG also regulates the inflammatory response via FcγRIIIa and FcγRIIIb. In particular, afucosylated IgG1 has a higher affinity for FcγRIIIa and FcγRIIIb due to an unusual, stabilizing sugar–sugar interaction. The role of afucosylated Fc glycoforms in regulating inflammatory responses has been well demonstrated in dengue infection, where antibodies play a direct role in mediating severe diseases, dengue hemorrhagic fever and dengue shock syndrome [ 14, 74]. Figure 5

IgG glycosylation and inflammation

IgG glycosylation affects antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and neutrophil activation, thus demonstrating the critical role of IgG glycans in effector functions [75]. Removal of the core fucose of IgG improves clinical efficacy by enhancing ADCC-mediated killing. Afucosylated IgG has a higher affinity for FcγRIIIA and FcγRIIIB, and ADCC increases 100 times more than fucosylated IgG. This phenomenon is heavily exploited in the production of monoclonal antibodies (mAbs) that are dependent on ADCC processes [76]. The incorporation of bisecting GlcNAc has a similar effect on ADCC, albeit with much weaker potency [ 76, 77]. Increased sialylation of IgG promotes ADCC, leading to the conversion of intravenous immunoglobulins from a pro-inflammatory state to an anti-inflammatory state [69].

Changes in IgG Glycan with Biological Aging

In recent years, the suggestion that IgG glycans are promising biomarkers for predicting biological age has garnered significant attention in research and clinical fields. Several studies have revealed reasonable correlations between specific IgG glycan structures and an individual’s biological age, suggesting their utility in assessing aging processes. Krištić et al. [57] observed a negative association between age and the abundance of monosialylated and disialylated IgG glycans in all examined groups of individuals [ 57, 78]. By utilizing these markers, researchers have begun to predict biological age accurately, offering insights into an individual’s overall aging status and susceptibility to age-related diseases. A new glycomic age index combining one agalactosylated glycan (GP6) and two digalactosylated glycans (GP14 and GP15) has been developed based on the results of the study, although it predicts the actual age with an error of 9.7 years, which is closely related to various biochemical and physiological characteristics reflecting biological aging. Exceptionally, IgG galactosylation is strongly correlated with age, and the development of high-throughput methods for glycan analysis has allowed replication of the results of small-sample studies in cohorts involving thousands of individuals, ultimately confirming an age-related trend in IgG galactosylation, as evidenced primarily by an age-related decrease in digalactosylated and galactosylated IgG glycoforms and a concomitant increase in agalactosylated IgG glycoforms [ 54, 79‒ 81]. This hypothesis is further supported by the observed decrease in galactosylation in some premature aging syndromes [82].

In conclusion, in both men and women, galactosylation and sialylation of IgG decrease with age, with the latter decreasing most dramatically during menopause but showing a transient increase during pregnancy, suggesting hormonal regulation [78]. Studies have shown that fluctuations in estrogen and progesterone levels can lead to variations in the levels of galactosylation and sialylation of IgG. For instance, increased estrogen levels during the follicular phase are associated with increased IgG galactosylation, whereas the luteal phase, characterized by elevated progesterone levels, tends to decrease IgG galactosylation [78]. In addition, IgG glycomic profiles, especially monogalactosylation profiles, are significantly different between and within various ethnic populations [83]. Additionally, research indicates that in addition to alterations in galactosylation and sialylation, other aspects of IgG glycosylation remain relatively stable throughout the human lifespan. Specifically, the levels of bisecting GlcNAc, another type of glycan modification, show minimal changes over time. Similarly, sialylation of the Fc region appears to undergo little variation across different stages of life [ 80, 84]. These findings suggest a nuanced regulatory mechanism governing IgG glycosylation dynamics, where certain modifications are influenced by hormonal fluctuations, while others maintain a steady state despite aging processes. Mouse models are widely used to study the mechanisms of physiological and pathological conditions in humans, which can be used to rule out genetic or environmental influences on IgG glycosylation. An N-glycome analysis of IgG in 589 mice with different genetic backgrounds revealed that different strains of mice exhibited certain differences in IgG N-glycosylation [85]. The detailed characteristics of IgG N-glycosylation in C57BL/6 mice of different ages also provide necessary references for investigating the function of IgG glycosylation in age-related studies [86]. Further investigation into the specific mechanisms underlying these glycosylation patterns using mouse models could provide valuable insights into the interplay between hormonal regulation, aging, and immune function.

Changes in IgG Glycan Levels in Patients with Aging-Related Diseases

Alterations in IgG glycosylation with aging have been implicated in the dysregulation of immune responses, impaired clearance of harmful molecules, and altered interactions with immune cells, thereby contributing to the pathogenesis of various age-related diseases ( Figure 6). Summarizing these IgG glycosylation alterations associated with different age-related diseases could enhance our comprehensive understanding of the functions of IgG glycosylation in various physiological and pathological conditions. Figure 6

Changes in IgG glycosylation in aging-related diseases

Neurodegenerative diseases

Alterations in IgG glycosylation patterns are present in various neurodegenerative diseases, including Alzheimer’s disease (AD) [87], Parkinson’s disease (PD) [88], and amyotrophic lateral sclerosis (ALS) [89]. Specifically, changes in the composition and structure of IgG glycan molecules have been observed in the serum and cerebrospinal fluid of affected individuals.

In Alzheimer’s disease, aberrant IgG glycosylation has been associated with the aggregation and deposition of amyloid-beta plaques, a hallmark pathology of the disease. Research has shown that AD patients have an altered glycan profile, with an increase in fucosylated glycoforms and a decrease in galactosylated and sialylated glycoforms [87]. A case–control study revealed that decreased sialylation and core fucosylation and increased bisecting N-acetylglucosamine (GlcNAc) N-glycan structures were significantly different between patients with dementia and those with normal cognitive functioning [90]. These glycosylation changes may affect the clearance mechanisms responsible for removing amyloid-beta from the brain, thereby exacerbating its accumulation and contributing to neuronal dysfunction and cognitive decline. In addition, to determine whether serum glycopeptide analysis has the potential to identify a new diagnosis and prognosis of AD, researchers found that the fucosylation status of IgG was able to distinguish AD patients from healthy controls. Specifically, an increased abundance of non-fucosylated IgG1 and IgG2 was observed in AD patients compared with controls [91].

In Parkinson’s disease, similar alterations in IgG glycosylation have been linked to the misfolding and aggregation of alpha-synuclein protein, leading to the formation of Lewy bodies, which are characteristic pathological features of the disease. A reduced level of sialylation, particularly monosialylation, was observed in PD patients, with reduced relative abundances of biantennary digalactosylated monosialylated glycans (GP17), biantennary digalactosylated disialylated glycans (GP21), biantennary galactosylated sialylated glycans (FGS/(FG+FGS)), biantennary monogalactosylated monosialylated glycans (FG1S1/(FG1+ FG1S1)), and biantennary digalactosylated monosialylated glycans (FG2S1/(FG2+FG2S1+FG2S2)). These effects lead to reduced inhibition of Fcγ-RIIIa binding and elevated antibody-dependent cell cytotoxicity (ADCC) activation in PD [88]. Furthermore, in individuals with ALS, changes in IgG glycosylation have been associated with the dysregulation of immune responses and the activation of inflammatory pathways within the central nervous system. Alterations in IgG glycosylation have also been reported in patients with ALS, with reduced galactosylation and increased bisecting GlcNAc and IgG glycosylation differing between cerebrospinal fluid and serum [ 92, 93]. These alterations may contribute to the progressive degeneration of motor neurons observed in ALS patients.

Cardiovascular disease

IgG glycans can be used to predict acute cardiovascular events, the composition of which correlates with the risk of cardiovascular disease (CVD). Agalactosylated, monogalactosylated, and sialylated N-glycans with a bisecting GlcNAc have a positive association with CVD, whereas sialylated glycans without a bisecting GlcNAc have a negative association [94]. Birukov et al. [95] investigated the IgG N-glycome composition in 2175 individuals from the EPIC-Potsdam cohort, including 417 patients with myocardial infarction (MI) and stroke. They discovered a sex-dependent association between the presence of IgG glycans and the incidence of MI/stroke. In males, a weighted score derived from FA2BG2S1 and FA2G2S2 was linked to an increased risk of CVD. Conversely, in females, the FA2[3]G1 structure on IgG showed an inverse association with CVD risk [ 96, 95].

Coronary artery disease (CAD) is the most common cardiovascular disease, and previous studies have shown a significant association between CAD and the N-glycosylation of IgG. Specifically, a sex-stratified analysis of 316 patients with coronary atherosclerosis and 156 subjects with clean coronaries revealed differences in the IgG N-glycome composition. Interestingly, the most significant differences were observed in women, where the presence of sialylated N-glycan structures was negatively correlated with CAD [97]. Abnormal IgG glycosylation has been associated with endothelial dysfunction, oxidative stress, and thrombotic events in coronary artery disease. These glycosylation alterations may influence the pro-inflammatory and pro-thrombotic properties of IgG antibodies, contributing to the pathogenesis of CAD [97].

In atherosclerosis, changes in IgG glycosylation have been linked to the inflammatory processes underlying plaque formation and progression. A cross-sectional study revealed that increased levels of bisecting GlcNAc in the IgG N-glycome were positively correlated with the presence of atherosclerotic plaques in carotid and femoral arteries. Conversely, sialylated glycans lacking bisecting GlcNAc were negatively associated with each other [94]. Dysregulated glycosylation of IgG antibodies may modulate their interactions with immune cells and circulating lipoproteins, exacerbating vascular inflammation and promoting atherosclerotic lesion development. Wu et al. [98] conducted a cross-sectional study enrolling 1465 individuals aged between 40 and 70 years from the Busselton Health and Aging Study. They employed machine learning techniques such as recursive feature elimination and penalized regression algorithms to systematically screen for significant glycans and construct an IgG N-glycosylation cardiovascular age (GlyCage) index. Notably, fucosylated N-glycans with bisecting GlcNAc (GP6, FA2B) and bis-galactosylated N-glycans with bifurcated GlcNAc (GP13, A2BG2) were found to make the most substantial contributions to the index.

Metabolic disorders

The role of IgG glycosylation in metabolic diseases is increasingly recognized. Dysregulation of IgG glycosylation has been implicated in various metabolic disorders, including obesity, diabetes, and dyslipidemia [ 99‒ 101]. A high body mass index (BMI) is commonly used as a criterion for obesity, but when using the IgG glycome as a biomarker, the waist-to-hip ratio should be used instead of BMI, as it has been shown that individuals with a normal BMI who have central adiposity (as measured by the waist-to-hip ratio) have lower levels of galactosylation and bisecting GlcNAc and higher fucosylation [ 99, 102]. Importantly, hyposialylated IgG can activate the endothelial IgG receptor FcγRIIB to promote obesity-induced insulin resistance [100]. The common types of diabetes are type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Studies have shown that the onset of type 1 diabetes is associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation [103]. Furthermore, Liu et al. [104] observed a decrease in bisecting N-acetylglucosamine of IgG2 and agalactosylation of IgG4 and an increase in sialylation of IgG4 and digalactosylation of IgG2 in T2DM patients. In addition, Plomp et al. [105] reported a positive association between IgG1 fucosylation and insulin levels and between IgG4 galactosylation and sialylation and insulin, as well as a positive association between IgG4 bisection and glucose. Age-related changes in IgG glycosylation in T2DM patients have been highlighted in several studies, and age-related increases in α2,3-linked and α2,6-linked sialylation on fucosylated glycans have been observed, suggesting a potential link between aging and chronic inflammation and disease exacerbation [106].

Dyslipidemia is another common metabolic disease and a key contributor to atherosclerosis. In dyslipidemia, inflammation is driven not only by abnormal glycosylation of lipoproteins but also by modifications of IgG glycans. Reductions in galactose and sialic acid residues, together with the introduction of bisecting GlcNAc on IgG glycans, may contribute to the persistent inflammation observed during the development and progression of dyslipidemia [ 101, 107]. Understanding the alterations in IgG glycans, such as changes in galactose and sialic acid residues and the presence of bisecting GlcNAc, provides insights into the underlying mechanisms of inflammation in conditions such as dyslipidemia.

Autoimmune and inflammatory diseases

The activity and interaction of IgG, a critical component of humoral immunity, with other immune cells and molecules can be largely influenced by glycosylation. Rheumatoid arthritis (RA) was the first disease reported to be associated with altered IgG glycosylation [108]. A decrease in galactosylated and sialylated IgG glycans was found in patients with RA [ 109‒ 111]. Other researchers have used lectin microarrays to detect higher levels of fucosylation in the plasma of RA patients [112]. These glycosylation changes may affect the functional properties of IgG, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and inflammatory regulation. Specifically, reduced galactosylation may reduce the anti-inflammatory function of IgG, whereas increased sialylation may enhance its anti-inflammatory effects [113]. In addition, the ratio of serum G0/G1 (non-galactosylated to monogalactosylated) can serve as a diagnostic marker to distinguish RA patients from healthy individuals as early as 3.5 years prior to the onset of the disease [114].

In a collagen-induced arthritis (CIA) model, genetic blockade of sialylation in activated B cells tends to increase joint inflammation. Conversely, artificial glycosylation of anti-type II collagen antibodies, including anti-citrullinated peptide antibodies (ACPAs), not only attenuates arthritis-inducing activity but also inhibits the development of CIA in antibody-pretreated mice. Notably, glycosylation of other IgGs does not prevent CIA [115]. In another study, TH17 cells regulated the expression of β-galactoside α2,6-sialyltransferase 1 in newly differentiated antibody-producing cells by directing B cells in an IL-22- and IL-21-dependent manner. This regulation determines the glycosylation profile and activity of IgG produced by subsequent plasma cells. Asymptomatic patients with RA-specific autoantibodies exhibit similar changes in the activity and glycosylation of autoreactive IgG antibodies before they enter the inflammatory phase of RA [116]. Additionally, certain autoimmune and inflammatory diseases, such as multiple sclerosis (MS) [117] and systemic lupus erythematosus (SLE) [118], exhibit significantly different IgG glycomic profiles. Although these conditions are influenced by age, they are primarily categorized as autoimmune diseases rather than aging-related diseases and thus will not be discussed in detail here.

Overall, the above studies on aging-related diseases suggest that IgG glycosylation may play a significant role in disease pathogenesis by influencing protein aggregation, immune responses, and chronic inflammation ( Table 1). Further investigation into the underlying mechanisms of IgG glycosylation dysregulation may provide insights into potential therapeutic targets for the treatment of these devastating conditions. Table 1 Altered IgG glycosylation in age-related diseases

Diseases

	Samples

	Increased glycoforms

	Decreased glycoforms

	Year

	Ref

	
AD

	Plasma

	Fucosylation

	Galactosylation and sialylation

	2014

	[87]

	
Plasma

	Bisecting GlcNAc

	Sialylation and core fucosylation

	2021

	[90]

	
Plasma

	Non‐fucosylated IgG1 and IgG2

		2022

	[91]

	
PD

	Plasma

	Galactosylation

	Sialylation

	2017

	[88]

	
ALS

	Plasma and cerebrospinal fluid

	Bisecting GlcNAc

	Galactosylation

	2015

	[93]

	
Cerebrospinal fluid

		Galactosylation

	2019

	[92]

	
Cardiovascular disease

	Plasma

	Agalactosylated, monogalactosylated, and sialylated glycans with bisecting GlcNAc

	Sialylated glycans without bisecting GlcNAc

	2021

	[119]

	
Plasma

	Galactosylated and sialylated fucosylated glycoforms without bisecting GlcNAc

		2022

	[ 95, 96]

	
Atherosclerosis

	Plasma

	Bisecting GlcNAc

		2018

	[94]

	
Coronary artery disease

	Plasma

		Sialylation

	2023

	[97]

	
Central adiposity

	Plasma

	Fucosylation

	Galactosylation

and bisecting GlcNAc

	2019

	[ 99, 102]

	
Type 1 diabetes mellitus

	Plasma

	High-mannose, bisecting GlcNAc

and disialylation

	Monogalactosylation

	2022

	[103]

	
Plasma

	Galactosylation

and sialylation

	Simple biantennary N-glycans

	2018

	[120]

	
Type 2 diabetes mellitus

	Plasma

	Sialylation of IgG4 and digalactosylation of IgG2

	Agalactosylation of IgG4 and bisecting N-GlcNAc of IgG2

	2019

	[104]

	
Plasma

	IgG4 bisection

		2017

	[105]

	
Dyslipidemia

	Plasma

	Bisecting GlcNAc

	Galactosylation and sialylation

	2018

	[ 101, 107]

	
Rheumatoid arthritis

	Plasma

	Fucosylation

	Galactosylation and sialylation

	2023

	[ 111, 112]

	

Conclusions

The altered glycosylation patterns observed on IgG in aging-related diseases underscore the intricate interplay between immune function, inflammation, and aging processes. The distinct changes in IgG glycosylation profiles, including reductions in galactosylation and sialylation, alongside increases in agalactosylation and bisecting GlcNAc, serve as potential biomarkers for assessing aging-related pathologies. These glycan modifications reflect underlying physiological changes associated with aging, inflammation, and immune dysregulation, highlighting the importance of IgG glycosylation as a promising avenue for understanding and diagnosing aging-related diseases.

Further research is warranted to elucidate the mechanisms underlying alterations in IgG glycosylation in aging-related diseases and their functional implications. This includes investigating the causal relationships between specific glycan structures and disease pathogenesis, as well as exploring the potential of IgG glycan-based interventions for disease prevention and treatment. IgG glycosylation is strongly influenced by genetic and environmental factors, including age, gender, ethnicity and geographic distributions. It is therefore necessary to integrate IgG glycan biomarkers with other types of biomarkers discovered by genomics, proteomics, and metabolomics to comprehensively assess age-related phenotypes. This holistic approach could provide deeper insights into the complex interplay between molecular pathways underlying aging processes and open up avenues for the development of innovative interventions aimed at promoting healthy aging and extending lifespan.

In summary, the study of altered IgG glycosylation in aging-related diseases as well as during natural physiological aging holds significant promise for advancing our understanding of glycosylation functions and disease mechanisms, improving diagnostic strategies, and ultimately enhancing therapeutic interventions to promote healthy aging and mitigate age-related pathologies.

COMPETING INTERESTS

The authors declare that they have no conflict of interest.
==== Refs
1 da Costa JP Vitorino R Silva GM Vogel C Duarte AC Rocha-Santos T A synopsis on aging—theories, mechanisms and future prospects Ageing Res Rev 2016 29 90 112 10.1016/j.arr.2016.06.005 27353257
2 López-Otín C Blasco MA Partridge L Serrano M Kroemer G Hallmarks of aging: an expanding universe Cell 2023 186 243 278 10.1016/j.cell.2022.11.001 36599349
3 Zhang J Wang S Liu B New insights into the genetics and epigenetics of aging plasticity Genes 2023 14 329 10.3390/genes14020329 36833255
4 Guo J Huang X Dou L Yan M Shen T Tang W Li J Aging and aging-related diseases: from molecular mechanisms to interventions and treatments Sig Transduct Target Ther 2022 7 391 10.1038/s41392-022-01251-0
5 Kennedy BK Berger SL Brunet A Campisi J Cuervo AM Epel ES Franceschi C et al. Geroscience: linking aging to chronic disease Cell 2014 159 709 713 10.1016/j.cell.2014.10.039 25417146
6 Franceschi C Garagnani P Morsiani C Conte M Santoro A Grignolio A Monti D et al. The continuum of aging and age-related diseases: common mechanisms but different rates Front Med 2018 5 61 10.3389/fmed.2018.00061
7 Schjoldager KT Narimatsu Y Joshi HJ Clausen H Global view of human protein glycosylation pathways and functions Nat Rev Mol Cell Biol 2020 21 729 749 10.1038/s41580-020-00294-x 33087899
8 Özdemir V Arga KYı Aziz RK Bayram M Conley SN Dandara C Endrenyi L et al. Digging deeper into precision/personalized medicine: cracking the sugar code, the third alphabet of life, and sociomateriality of the cell OMICS-J Integr Biol 2020 24 62 80 10.1089/omi.2019.0220
9 Mariño K Bones J Kattla JJ Rudd PM A systematic approach to protein glycosylation analysis: A path through the maze Nat Chem Biol 2010 6 713 723 10.1038/nchembio.437 20852609
10 Wang W Glycomedicine: the current state of the art Engineering 2023 26 12 15 10.1016/j.eng.2022.03.009
11 Hu M Zhang R Yang J Zhao C Liu W Huang Y Lyu H et al. The role of N-glycosylation modification in the pathogenesis of liver cancer Cell Death Dis 2023 14 222 10.1038/s41419-023-05733-z 36990999
12 Wilson MP Matthijs G The evolving genetic landscape of congenital disorders of glycosylation Biochim Biophys Acta Gen Subj 2021 1865 129976 10.1016/j.bbagen.2021.129976 34358634
13 Vanhooren V Laroy W Libert C Chen C N-Glycan profiling in the study of human aging Biogerontology 2008 9 351 356 10.1007/s10522-008-9140-z 18431686
14 Wang T T. IgG Fc glycosylation in human immunity. Curr Top Microbiol Immunol 2019, 423: 63–75
15 Buhre JS Becker M Ehlers M IgG subclass and Fc glycosylation shifts are linked to the transition from pre- to inflammatory autoimmune conditions Front Immunol 2022 13 1006939 10.3389/fimmu.2022.1006939 36405742
16 Wang J Huang C Zhou J Zhao K Li Y Causal link between immunoglobulin G glycosylation and cancer: a potential glycobiomarker for early tumor detection Cell Immunol 2021 361 104282 10.1016/j.cellimm.2021.104282 33453507
17 Haslund-Gourley BS Wigdahl B Comunale MA IgG N-glycan signatures as potential diagnostic and prognostic biomarkers Diagnostics 2023 13 1016 10.3390/diagnostics13061016 36980324
18 Gudelj I Lauc G Pezer M Immunoglobulin G glycosylation in aging and diseases Cell Immunol 2018 333 65 79 10.1016/j.cellimm.2018.07.009 30107893
19 Sun Y Huang T Hammarström L Zhao Y The immunoglobulins: new insights, implications, and applications Annu Rev Anim Biosci 2020 8 145 169 10.1146/annurev-animal-021419-083720 31846352
20 Yagi H, Yanaka S, Kato K. Structure and dynamics of immunoglobulin G glycoproteins. Adv Exp Med Biol 2018, 1104: 219–235
21 Shkunnikova S Mijakovac A Sironic L Hanic M Lauc G Kavur MM IgG glycans in health and disease: prediction, intervention, prognosis, and therapy Biotechnol Adv 2023 67 108169 10.1016/j.biotechadv.2023.108169 37207876
22 Hoffman W Lakkis FG Chalasani G B cells, antibodies, and more Clin J Am Soc Nephrol 2016 11 137 154 10.2215/CJN.09430915 26700440
23 Arnold JN Wormald MR Sim RB Rudd PM Dwek RA The impact of glycosylation on the biological function and structure of human immunoglobulins Annu Rev Immunol 2007 25 21 50 10.1146/annurev.immunol.25.022106.141702 17029568
24 Qiu X, Zhu X, Zhang L, Mao Y, Zhang J, Hao P, Li G, et al. Human epithelial cancers secrete immunoglobulin g with unidentified specificity to promote growth and survival of tumor cells. Cancer Res 2003, 63: 6488–6495.
25 Vidarsson G Dekkers G Rispens T IgG subclasses and allotypes: from structure to effector functions Front Immunol 2014 5 520 10.3389/fimmu.2014.00520 25368619
26 Rashid MH Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation mAbs 2022 14 2111748 10.1080/19420862.2022.2111748 36018829
27 Scapin G Yang X Prosise WW McCoy M Reichert P Johnston JM Kashi RS et al. Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab Nat Struct Mol Biol 2015 22 953 958 10.1038/nsmb.3129 26595420
28 Saphire EO Parren PWHI Pantophlet R Zwick MB Morris GM Rudd PM Dwek RA et al. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design Science 2001 293 1155 1159 10.1126/science.1061692 11498595
29 Harris LJ Larson SB Hasel KW McPherson A Refined Structure of an Intact IgG2a Monoclonal Antibody , Biochemistry 1997 36 1581 1597 10.1021/bi962514+ 9048542
30 Harris LJ Skaletsky E McPherson A Crystallographic structure of an intact IgG1 monoclonal antibody J Mol Biol 1998 275 861 872 10.1006/jmbi.1997.1508 9480774
31 Ferrante A, Beard LJ, Feldman RG. IgG subclass distribution of antibodies to bacterial and viral antigens. Pediatr Infect Dis J 1990, 9: S16–S24.
32 Jefferis R Kumararatne DS Selective IgG subclass deficiency: quantification and clinical relevance Clin Exp Immunol 1990 81 357 367 10.1111/j.1365-2249.1990.tb05339.x 2204502
33 Siber GR Schur PH Aisenberg AC Weitzman SA Schiffman G Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens N Engl J Med 1980 303 178 182 10.1056/NEJM198007243030402 6966763
34 Stapleton NM Andersen JT Stemerding AM Bjarnarson SP Verheul RC Gerritsen J Zhao Y et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential Nat Commun 2011 2 599 10.1038/ncomms1608 22186895
35 Aalberse RC, van der Gaag R, van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 1983, 130: 722–726.
36 Helenius A Aebi M Intracellular functions of N-Linked glycans Science 2001 291 2364 2369 10.1126/science.291.5512.2364 11269317
37 Reily C Stewart TJ Renfrow MB Novak J Glycosylation in health and disease Nat Rev Nephrol 2019 15 346 366 10.1038/s41581-019-0129-4 30858582
38 Anthony RM Wermeling F Ravetch JV Novel roles for the IgG Fc glycan Ann New York Acad Sci 2012 1253 170 180 10.1111/j.1749-6632.2011.06305.x 22288459
39 van de Bovenkamp FS Hafkenscheid L Rispens T Rombouts Y The emerging importance of IgG fab glycosylation in immunity J Immunol 2016 196 1435 1441 10.4049/jimmunol.1502136 26851295
40 Shen J Jia L Dang L Su Y Zhang J Xu Y Zhu B et al. StrucGP: De novo structural sequencing of site-specific N-glycan on glycoproteins using a modularization strategy Nat Methods 2021 18 921 929 10.1038/s41592-021-01209-0 34341581
41 Stadlmann J Pabst M Kolarich D Kunert R Altmann F Analysis of immunoglobulin glycosylation by LC‐ESI‐MS of glycopeptides and oligosaccharides Proteomics 2008 8 2858 2871 10.1002/pmic.200700968 18655055
42 De Leoz MLA Duewer DL Fung A Liu L Yau HK Potter O Staples GO et al. NIST interlaboratory study on glycosylation analysis of monoclonal antibodies: comparison of results from diverse analytical methods Mol Cell Proteomics 2020 19 11 30 10.1074/mcp.RA119.001677 31591262
43 Holland M Yagi H Takahashi N Kato K Savage COS Goodall DM Jefferis R Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis Biochim Biophys Acta Gen Subj 2006 1760 669 677 10.1016/j.bbagen.2005.11.021
44 Stavenhagen K Gahoual R Dominguez Vega E Palmese A Ederveen ALH Cutillo F Palinsky W et al. Site-specific N- and O-glycosylation analysis of atacicept mAbs 2019 11 1053 1063 10.1080/19420862.2019.1630218 31349756
45 Kim H Yamaguchi Y Masuda K Matsunaga C Yamamoto K Irimura T Takahashi N et al. O-glycosylation in hinge region of mouse immunoglobulin G2b J Biol Chem 1994 269 12345 12350 10.1016/S0021-9258(17)32722-9 7512967
46 Mattu TS Pleass RJ Willis AC Kilian M Wormald MR Lellouch AC Rudd PM et al. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-Glycosylation on Fcα receptor interactions J Biol Chem 1998 273 2260 2272 10.1074/jbc.273.4.2260 9442070
47 Takahashi N Tetaert D Debuire B Lin LC Putnam FW Complete amino acid sequence of the delta heavy chain of human immunoglobulin D Proc Natl Acad Sci USA 1982 79 2850 2854 10.1073/pnas.79.9.2850 6806818
48 Plomp R Dekkers G Rombouts Y Visser R Koeleman CAM Kammeijer GSM Jansen BC et al. Hinge-region O-Glycosylation of human immunoglobulin G3 (IgG3) Mol Cell Proteomics 2015 14 1373 1384 10.1074/mcp.M114.047381 25759508
49 Jennewein MF Alter G The immunoregulatory roles of antibody glycosylation Trends Immunol 2017 38 358 372 10.1016/j.it.2017.02.004 28385520
50 Chung CY Majewska NI Wang Q Paul JT Betenbaugh MJ SnapShot: N-Glycosylation processing pathways across kingdoms Cell 2017 171 258 258.e1 10.1016/j.cell.2017.09.014 28938118
51 Cui Y Li J Zhang P Yin D Wang Z Dai J Wang W et al. B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma J Exp Clin Cancer Res 2023 42 146 10.1186/s13046-023-02711-3 37303063
52 Parekh R Roitt I Isenberg D Dwek R Rademacher T Age-related galactosylation of the N-linked oligosaccharides of human serum IgG J Exp Med 1988 167 1731 1736 10.1084/jem.167.5.1731 3367097
53 Pezer M Stambuk J Perica M Razdorov G Banic I Vuckovic F Gospic AM et al. Effects of allergic diseases and age on the composition of serum IgG glycome in children Sci Rep 2016 6 33198 10.1038/srep33198 27616597
54 de Haan N Reiding KR Driessen G van der Burg M Wuhrer M Changes in healthy human IgG Fc-glycosylation after birth and during early childhood J Proteome Res 2016 15 1853 1861 10.1021/acs.jproteome.6b00038 27161864
55 Catera M Borelli V Malagolini N Chiricolo M Venturi G Reis CA Osorio H et al. Identification of novel plasma glycosylation-associated markers of aging Oncotarget 2016 7 7455 7468 10.18632/oncotarget.7059 26840264
56 van de Geijn FE Wuhrer M Selman MH Willemsen SP de Man YA Deelder AM Hazes JM et al. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study Arthritis Res Ther 2009 11 R193 10.1186/ar2892 20015375
57 Krištić J Vučković F Menni C Klarić L Keser T Beceheli I Pučić-Baković M et al. Glycans are a novel biomarker of chronological and biological ages J Gerontol A Biol Sci Med Sci 2014 69 779 789 10.1093/gerona/glt190 24325898
58 Kaneko Y Nimmerjahn F Ravetch JV Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation Science 2006 313 670 673 10.1126/science.1129594 16888140
59 Cheng HD Tirosh I de Haan N Stöckmann H Adamczyk B McManus CA O’Flaherty R et al. IgG Fc glycosylation as an axis of humoral immunity in childhood J Allergy Clin Immunol 2020 145 710 713.e9 10.1016/j.jaci.2019.10.012 31669096
60 Sun Y Li X Wang T Li W Core fucosylation regulates the function of pre-BCR, BCR and IgG in humoral immunity Front Immunol 2022 13 844427 10.3389/fimmu.2022.844427 35401499
61 Zauner G Selman MHJ Bondt A Rombouts Y Blank D Deelder AM Wuhrer M Glycoproteomic analysis of antibodies Mol Cell Proteomics 2013 12 856 865 10.1074/mcp.R112.026005 23325769
62 Li J Liu D Zhang Y Shen J Dan W Chen Z Sun S Site-specific analysis of core and antenna fucosylation on serum glycoproteins Anal Chem 2024 96 5741 5745 10.1021/acs.analchem.4c00445 38573003
63 Pučić M Mužinić A Novokmet M Škledar M Pivac N Lauc G Gornik O Changes in plasma and IgG N-glycome during childhood and adolescence Glycobiology 2012 22 975 982 10.1093/glycob/cws062 22426998
64 Taniguchi N Ohkawa Y Maeda K Harada Y Nagae M Kizuka Y Ihara H et al. True significance of N-acetylglucosaminyltransferases GnT-III, V and α1,6 fucosyltransferase in epithelial-mesenchymal transition and cancer Mol Aspects Med 2021 79 100905 10.1016/j.mam.2020.100905 33010941
65 Dang L Li P Dan W Liu H Shen J Zhu B Jia L et al. Glycoproteomic analysis of regulatory effects of bisecting N-glycans on N-glycan biosynthesis and protein expressions in human HK-2 cells Carbohydrate Res 2023 531 108894 10.1016/j.carres.2023.108894
66 Dan W Li C Li J Li P Xin M Chen Z Dang L et al. Glycoproteomic analysis reveals the effects of bisecting GlcNAc in intrahepatic cholangiocarcinoma Glycoconj J 2022 39 737 745 10.1007/s10719-022-10085-5 36322335
67 Ding N Nie H Sun X Sun W Qu Y Liu X Yao Y et al. Human serum N-glycan profiles are age and sex dependent Age Ageing 2011 40 568 575 10.1093/ageing/afr084 21807702
68 Thulin NK, Wang TT. The role of Fc gamma receptors in broad protection against influenza viruses. Vaccines (Basel) 2018, 6: 36
69 Schwab I Nimmerjahn F Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013 13 176 189 10.1038/nri3401 23411799
70 Raju TS Terminal sugars of Fc glycans influence antibody effector functions of IgGs Curr Opin Immunol 2008 20 471 478 10.1016/j.coi.2008.06.007 18606225
71 Anthony RM Nimmerjahn F Ashline DJ Reinhold VN Paulson JC Ravetch JV Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc Science 2008 320 373 376 10.1126/science.1154315 18420934
72 Washburn N Schwab I Ortiz D Bhatnagar N Lansing JC Medeiros A Tyler S et al. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity Proc Natl Acad Sci USA 2015 112 E1297 E1306 10.1073/pnas.1422481112 25733881
73 Yu HR Chang WP Wang L Lin YJ Liang CD Yang KD Kuo CM et al. DC-SIGN (CD209) promoter-336 A/G (rs4804803) polymorphism associated with susceptibility of Kawasaki disease Sci World J 2012 2012 1 5 10.1100/2012/634835
74 Ferrara C Grau S Jäger C Sondermann P Brünker P Waldhauer I Hennig M et al. Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose Proc Natl Acad Sci USA 2011 108 12669 12674 10.1073/pnas.1108455108 21768335
75 Jefferis R Glycosylation as a strategy to improve antibody-based therapeutics Nat Rev Drug Discov 2009 8 226 234 10.1038/nrd2804 19247305
76 Masuda K Kubota T Kaneko E Iida S Wakitani M Kobayashi-Natsume Y Kubota A et al. Enhanced binding affinity for FcγRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity Mol Immunol 2007 44 3122 3131 10.1016/j.molimm.2007.02.005 17379311
77 Davies J Jiang LY Pan L‐ LaBarre MJ Anderson D Reff M Expression of GnTIII in a recombinant anti‐CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FCγRIII Biotech Bioeng 2001 74 288 294 10.1002/bit.1119
78 Chen G Wang Y Qiu L Qin X Liu H Wang X Wang Y et al. Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer J Proteomics 2012 75 2824 2834 10.1016/j.jprot.2012.02.001 22365975
79 Vanhooren V Desmyter L Liu XE Cardelli M Franceschi C Federico A Libert C et al. N-Glycomic changes in serum proteins during human aging Rejuvenation Res 2007 10 521 531a 10.1089/rej.2007.0556 18047421
80 Yu X Wang Y Kristic J Dong J Chu X Ge S Wang H et al. Profiling IgG N-glycans as potential biomarker of chronological and biological ages Medicine 2016 95 e4112 10.1097/MD.0000000000004112 27428197
81 Nimmerjahn F Anthony RM Ravetch JV Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity Proc Natl Acad Sci USA 2007 104 8433 8437 10.1073/pnas.0702936104 17485663
82 Vanhooren V Dewaele S Libert C Engelborghs S De Deyn PP Toussaint O Debacq-Chainiaux F et al. Serum N-glycan profile shift during human ageing Exp Gerontology 2010 45 738 743 10.1016/j.exger.2010.08.009
83 Štambuk J Nakić N Vučković F Pučić-Baković M Razdorov G Trbojević-Akmačić I Novokmet M et al. Global variability of the human IgG glycome Aging 2020 12 15222 15259 10.18632/aging.103884 32788422
84 Pučić M Knežević A Vidič J Adamczyk B Novokmet M Polašek O Gornik O et al. High throughput isolation and glycosylation analysis of IgG–variability and heritability of the IgG glycome in three isolated human populations Mol Cell Proteomics 2011 10 M111.010090 10.1074/mcp.M111.010090
85 Krištić J Zaytseva OO Ram R Nguyen Q Novokmet M Vučković F Vilaj M et al. Profiling and genetic control of the murine immunoglobulin G glycome Nat Chem Biol 2018 14 516 524 10.1038/s41589-018-0034-3 29632412
86 Han J Pan Y Gu Y Xu X Zhao R Sha J Zhang R et al. Profiling of IgG N-glycome during mouse aging: fucosylated diantennary glycans containing one Neu5Gc-linked LacNAc are associated with age J Proteomics 2020 229 103966 10.1016/j.jprot.2020.103966 32891889
87 Lundström SL Yang H Lyutvinskiy Y Rutishauser D Herukka SK Soininen H Zubarev RA Blood plasma IgG Fc glycans are significantly altered in alzheimer′s disease and progressive mild cognitive impairment J Alzheimer's Dis 2013 38 567 579 10.3233/JAD-131088
88 Russell AC Šimurina M Garcia MT Novokmet M Wang Y Rudan I Campbell H et al. The N-glycosylation of immunoglobulin G as a novel biomarker of Parkinson's disease Glycobiology 2017 27 501 510 10.1093/glycob/cwx022 28334832
89 Edri-Brami M Rosental B Hayoun D Welt M Rosen H Wirguin I Nefussy B et al. Glycans in sera of amyotrophic lateral sclerosis patients and their role in killing neuronal cells PLoS One 2012 7 e35772 10.1371/journal.pone.0035772 22666317
90 Zhang X Yuan H Lyu J Meng X Tian Q Li Y Zhang J et al. Association of dementia with immunoglobulin G N-glycans in a Chinese Han Population NPJ Aging Mech Dis 2021 7 3 10.1038/s41514-021-00055-w 33542243
91 Tena J Tang X Zhou Q Harvey D Barajas-Mendoza M Jin L Maezawa I et al. Glycosylation alterations in serum of Alzheimer's disease patients show widespread changes in N-glycosylation of proteins related to immune function, inflammation, and lipoprotein metabolism Alzheimers Dement (Amst) 2022 14 e12309 10.1002/dad2.12309 35496372
92 Costa J Streich L Pinto S Pronto-Laborinho A Nimtz M Conradt HS de Carvalho M Exploring cerebrospinal fluid IgG N-glycosylation as potential biomarker for amyotrophic lateral sclerosis Mol Neurobiol 2019 56 5729 5739 10.1007/s12035-019-1482-9 30674035
93 Wuhrer M Selman MHJ McDonnell LA Kümpfel T Derfuss T Khademi M Olsson T et al. Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid J Neuroinflamm 2015 12 235 10.1186/s12974-015-0450-1
94 Menni C Gudelj I Macdonald-Dunlop E Mangino M Zierer J Bešić E Joshi PK et al. Glycosylation profile of immunoglobulin G is cross-sectionally associated with cardiovascular disease risk score and subclinical atherosclerosis in two independent cohorts Circ Res 2018 122 1555 1564 10.1161/CIRCRESAHA.117.312174 29535164
95 Birukov A Plavša B Eichelmann F Kuxhaus O Hoshi RA Rudman N Štambuk T et al. Immunoglobulin G N-glycosylation signatures in incident type 2 diabetes and cardiovascular disease Diabetes Care 2022 45 2729 2736 10.2337/dc22-0833 36174116
96 Wittenbecher C Štambuk T Kuxhaus O Rudman N Vučković F Štambuk J Schiborn C et al. Plasma N-glycans as emerging biomarkers of cardiometabolic risk: a prospective investigation in the EPIC-potsdam cohort study Diabetes Care 2020 43 661 668 10.2337/dc19-1507 31915204
97 Radovani B Vučković F Maggioni AP Ferrannini E Lauc G Gudelj I IgG N-glycosylation is altered in coronary artery disease Biomolecules 2023 13 375 10.3390/biom13020375 36830744
98 Wu Z Guo Z Zheng Y Wang Y Zhang H Pan H Li Z et al. IgG N-glycosylation cardiovascular age tracks cardiovascular risk beyond calendar age Engineering 2023 26 99 107 10.1016/j.eng.2022.12.004
99 Liu D Li Q Dong J Li D Xu X Xing W Zhang X et al. The association between normal BMI with central adiposity and proinflammatory potential immunoglobulin G N-glycosylation Diabetes Metab Syndr Obes 2019 12 2373 2385 10.2147/DMSO.S216318 31814749
100 Tanigaki K Sacharidou A Peng J Chambliss KL Yuhanna IS Ghosh D Ahmed M et al. Hyposialylated IgG activates endothelial IgG receptor FcγRIIB to promote obesity-induced insulin resistance J Clin Invest 2018 128 309 322 10.1172/JCI89333 29202472
101 Liu D Chu X Wang H Dong J Ge SQ Zhao ZY Peng HL et al. The changes of immunoglobulin G N-glycosylation in blood lipids and dyslipidaemia J Transl Med 2018 16 235 10.1186/s12967-018-1616-2 30157878
102 Nikolac Perkovic M Pucic Bakovic M Kristic J Novokmet M Huffman JE Vitart V Hayward C et al. The association between galactosylation of immunoglobulin G and body mass index Prog NeuropsychoPharmacol Biol Psychiatry 2014 48 20 25 10.1016/j.pnpbp.2013.08.014 24012618
103 Rudman N Kifer D Kaur S Simunović V Cvetko A Pociot F Morahan G et al. Children at onset of type 1 diabetes show altered N-glycosylation of plasma proteins and IgG Diabetologia 2022 65 1315 1327 10.1007/s00125-022-05703-8 35622127
104 Liu J Dolikun M Štambuk J Trbojević-Akmačić I Zhang J Zhang J Wang H et al. Glycomics for type 2 diabetes biomarker discovery: promise of immunoglobulin G subclass-specific fragment crystallizable N-glycosylation in the uyghur population OMICS-J Integr Biol 2019 23 640 648 10.1089/omi.2019.0052
105 Plomp R Ruhaak LR Uh HW Reiding KR Selman M Houwing-Duistermaat JJ Slagboom PE et al. Subclass-specific IgG glycosylation is associated with markers of inflammation and metabolic health Sci Rep 2017 7 12325 10.1038/s41598-017-12495-0 28951559
106 Štambuk T, Gornik O. Protein glycosylation in diabetes. Adv Exp Med Biol 2021, 1325: 285–305.
107 Huang J Lee H Zivkovic AM Smilowitz JT Rivera N German JB Lebrilla CB Glycomic analysis of high density lipoprotein shows a highly sialylated particle J Proteome Res 2014 13 681 691 10.1021/pr4012393 24417605
108 Parekh RB Dwek RA Sutton BJ Fernandes DL Leung A Stanworth D Rademacher TW et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG Nature 1985 316 452 457 10.1038/316452a0 3927174
109 Du N Song L Li Y Wang T Fang Q Ou J Nandakumar KS Phytoestrogens protect joints in collagen induced arthritis by increasing IgG glycosylation and reducing osteoclast activation Int Immunopharmacol 2020 83 106387 10.1016/j.intimp.2020.106387 32172207
110 Ho CH Chen SH Tsai HW Wu IC Chang TT Fully galactosyl-fucosyl-bisected IgG1 reduces anti-HBV efficacy and liver histological improvement Antiviral Res 2019 163 1 10 10.1016/j.antiviral.2018.12.021 30611775
111 Sun D Hu F Gao H Song Z Xie W Wang P Shi L et al. Distribution of abnormal IgG glycosylation patterns from rheumatoid arthritis and osteoarthritis patients by MALDI-TOF-MS n Analyst 2019 144 2042 2051 10.1039/C8AN02014K 30714583
112 Deng X Liu X Zhang Y Ke D Yan R Wang Q Tian X et al. Changes of serum IgG glycosylation patterns in rheumatoid arthritis Clin Proteom 2023 20 7 10.1186/s12014-023-09395-z
113 Kissel T Toes REM Huizinga TWJ Wuhrer M Glycobiology of rheumatic diseases Nat Rev Rheumatol 2023 19 28 43 10.1038/s41584-022-00867-4 36418483
114 Flögel M Lauc G Gornik I Maček B Fucosylation and galactosylation of IgG heavy chains differ between acute and remission phases of juvenile chronic arthritis Clin Chem Lab Med 1998 36 99 102 10.1515/CCLM.1998.018 9594046
115 Ohmi Y Ise W Harazono A Takakura D Fukuyama H Baba Y Narazaki M et al. Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis Nat Commun 2016 7 11205 10.1038/ncomms11205 27046227
116 Pfeifle R Rothe T Ipseiz N Scherer HU Culemann S Harre U Ackermann JA et al. Regulation of autoantibody activity by the IL-23–TH17 axis determines the onset of autoimmune disease Nat Immunol 2017 18 104 113 10.1038/ni.3579 27820809
117 Cvetko A Kifer D Gornik O Klarić L Visser E Lauc G Wilson JF et al. Glycosylation alterations in multiple sclerosis show increased proinflammatory potential Biomedicines 2020 8 410 10.3390/biomedicines8100410 33065977
118 Vučković F Krištić J Gudelj I Teruel M Keser T Pezer M Pučić-Baković M et al. Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome Arthritis Rheumatology 2015 67 2978 2989 10.1002/art.39273 26200652
119 Dashti H, Pabon Porras M A, Mora S. Glycosylation and cardiovascular diseases. Adv Exp Med Biol 2021,1325: 307–319
120 Bermingham ML Colombo M McGurnaghan SJ Blackbourn LAK Vučković F Pučić Baković M Trbojević-Akmačić I et al. N-glycan profile and kidney disease in type 1 diabetes Diabetes Care 2017 41 79 87 10.2337/dc17-1042 29146600
